



5th International Conference on Cardiomyopathy in Children

American College of Cardiology Conference Center | Washington D.C.
March 3 – March 4, 2021

Wednesday, March 3, 2021

7:30-8:00 am **Breakfast**

8:00-8:45 am **Welcome and Overview**

- Lisa Yue and Steven Lipshultz, MD

8:45-10:45 am

Dilated Cardiomyopathy

Session Leaders: Steve Lipshultz, MD, Daphne Hsu, MD, Paul Kantor, MBBCh, MSc

- How effectively do we currently risk stratify and tailor medical therapy for DCM?
Daphne Hsu, MD
- Which new drug therapies are under investigation for DCM?
Robert Shaddy, MD
- When and how does dilated cardiomyopathy recover?
Melanie Everitt, MD
- How do we improve quality and maximize value in the care of dilated cardiomyopathy?
Kimberly Lin, MD
- Point Counterpoint: How should we design research studies on dilated cardiomyopathy?
 - Observational studies are the most useful approach.
Bill Mahle, MD
 - Clinical trials are the most useful approach.
Christopher Almond, MD, MPH
- FDA perspective on approval of clinical trials.
Lynn Yao, MD
- General discussion and summary

10:45-11:00 am **Coffee Break**

11:00-12:15 pm

Hypertrophic Cardiomyopathy

Session Leaders: Charlie Canter, MD, Steve Colan, MD, Robert Weintraub, MBBS

- What are the differences between non-sarcomeric versus sarcomeric HCM and should they have their own management scheme?
Anne Murphy, MD
- Are P-G+ normal, diseased, or somewhere in between? / Role of genetic testing in clinical management?
Carolyn Ho, MD
- How should pediatric HCM be defined?
Steven Colan, MD
- What is the optimal imaging strategy for pediatric HCM: echo, MRI, or a hybrid approach? /What is the optimal evaluative or surveillance protocol for pediatric HCM, and the minimum dataset for ongoing clinical care?
Elfriede Pahl, MD
- How should HCM diagnosed in infancy be evaluated and managed?
Charlie Canter, MD
- Indications for surgical relief of LV outflow obstruction.
Robert Weintraub, MBBS
- Guided Discussion

12:15-1:15 pm

Lunch

1:15-2:25 pm

Hypertrophic Cardiomyopathy Continued

Session Leaders: Charlie Canter, MD, Steve Colan, MD , Robert Weintraub, MBBS

- What is the optimal management strategy to minimize sudden death in children with HCM?
Juan Kaski, MD
- Debate: the pros and cons of pediatric HCM±ICD participation in competitive athletics
George Van Hare, MD and Jeffrey Kim, MD
- The epidemiology and global burden of hypertrophic cardiomyopathy
Paul Barach, MD

2:25-2:40 pm

Afternoon Break

2:40-4:40 pm

Genetics of Cardiomyopathy

Session Leaders: Wendy Chung, MD, PhD, Shelley Miyamoto, MD, Stephanie Ware, MD, PhD

- Breaking News: Genetics of the primary cardiomyopathies.
Stephanie Ware, MD, PhD
- The CCF registry: providing the infrastructure for future pediatric cardiomyopathy research.
Wendy Chung, MD, PhD

- Update on gene-directed therapy for primary cardiomyopathies.
Anjali Owens, MD
- Which new gene therapies are under investigation?
Elizabeth McNally, MD, PhD
- Debate: Pros and cons of genetic testing.
Erin Miller, MS, GSC and Benjamin Helm, MS, GSC
- General discussion and summary
- The clinical utility of genetic testing in pediatric cardiomyopathy.
Andrew Landstrom, MD, PhD
- Panel Q&A

4:40-5:00 pm **Next Steps**

5:00 pm **Dinner and Presentation by Jerrica Mathis**

Thursday, March 4, 2021

8:00-8:30 am **Breakfast**

8:30-10:30 am **Restrictive Cardiomyopathy**
Session Leaders: Joseph Rossano, MD, Michael Burch MB, Ch B, MRCP, MSc

- Overview of current knowledge.
Susan Denfield, MD
- Risk stratification in RCM.
Michael Burch MB, Ch B, MRCP, MSc
- Secondary causes of RCM.
Yuk Law, MD
- Medical therapy for diastolic dysfunction: right around the corner or waiting for Godot?
Paul Kantor, MBBCh, MSc
- Moderated panel discussion
 - Moderators
Michael Burch MB, Ch B, MRCP, MSc, Joseph Rossano, MD
 - Panel
Robert Weintraub, MB BS, Susan Denfield, MD,
Jeff Towbin, MD, Shelley Miyamoto, MD

10:30-10:40 am **Coffee Break**

10:40-12:30 pm **Noncompaction Cardiomyopathy**
Session Leaders: Melanie Everitt, MD, Brian Feingold, MD, John Lynn Jefferies, MD, PhD

- Spectrum of phenotypes of ventricular noncompaction in children.
Jeff Towbin, MD

- Spectrum of phenotype of ventricular noncompaction in adults.
Eloisa Arbustini, MD
- Combined Q&A
Jeff Towbin, MD, Eloisa Arbustini, MD
- Molecular and histopathology of ventricular noncompaction.
Weinian Shou, PhD
- The role of imaging in diagnosis and evaluation of noncompaction.
Carolyn Taylor, MD
- Combined Q&A
Weinian Shou, PhD, Carolyn Taylor, MD
- Case presentations:
 - Isolated ventricular noncompaction.
Ashwin Lal, MD
 - CHD with ventricular noncompaction.
Thomas Ryan, MD
- Moderated Panel Discussion
 - Moderator
Brian Feingold, MD
 - Panel
John Lynn Jefferies, MD, MPH, Jeff Towbin, MD,
Eloisa Arbustini, MD, Carolyn Taylor, MD, Weinian Shou, PhD

12:30-1:15 pm

Lunch

1:15-3:15 pm

Arrhythmogenic Cardiomyopathy

Session Leaders: Jeff Towbin, MD, Teresa Lee, MD

- Clinical and genetic features of arrhythmogenic cardiomyopathy: the heart failure perspective.
Luisa Mestroni, MD
- Clinical and genetic features of arrhythmogenic cardiomyopathy: the electrophysiology perspective
Dominic Abrams, MD
- Pathophysiology of arrhythmogenic cardiomyopathy and protein/pathway targeted therapy
Jeffrey Saffitz, MD, PhD
- Gene based diagnostics and therapeutics
Teresa Lee, MD
- Diagnostic barriers
Pamela Woodard, MD
- Treatment barriers and exercise guidelines
Joseph Rossano, MD
- Next steps to achieving better outcomes
John Lynn Jefferies, MD, MPH

- General discussion and summary

3:15-4:00 pm

**Future Directions for the Pediatric Cardiomyopathy Community/Conference
Wrap Up**

Steven Colan, MD

4:00 pm

Meeting Adjourns

DRAFT